Sample size calculation for small sample single-arm trials for time-to-event data: Logrank test with normal approximation or test statistic based on exact chi-square distribution?

被引:13
作者
Phadnis, Milind A. [1 ]
机构
[1] Univ Kansas, Dept Biostat, Med Ctr, 3901 Rainbow Blvd, Kansas City, KS 66160 USA
关键词
Clinical trial; Exact test; Single-arm; Survival; Weibull; CLINICAL-TRIALS; SURVIVAL;
D O I
10.1016/j.conctc.2019.100360
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Sample size calculations are critical to the planning of a clinical trial. For single-arm trials with time-to-event endpoint, standard software provides only limited options. The most popular option is the log-rank test. A second option assuming exponential distribution is available on some online websites. Both these approaches rely on asymptotic normality for the test statistic and perform well for moderate-to-large sample sizes. Methods: As many new treatments in the field of oncology are cost-prohibitive and have slow accrual rates, researchers are often faced with the restriction of conducting single arm trials with potentially small-to-moderate sample sizes. As a practical solution, therefore, we consider the option of performing the sample size calculations using an exact parametric test with the test statistic following a chi-square distribution. Analytic results of sample size calculations from the two methods with Weibull distributed survival times are briefly compared using an example of a clinical trial on cholangiocarcinoma and are verified through simulations. Results: Our simulations suggest that in the case of small sample phase II studies, there can be some practical benefits in using the exact test that could affect the feasibility, timeliness, financial support, and 'clinical novelty' factor in conducting a study. The exact test is a good option for designing small-to-moderate sample trials when accrual and follow-up time are adequate. Conclusions: Based on our simulations for small sample studies, we conclude that a statistician should assess sensitivity of his calculations obtained through different methods before recommending a sample size to their collaborators.
引用
收藏
页数:7
相关论文
共 11 条
[1]  
[Anonymous], 2015, PASS 14 POW AN SAMPL
[2]   ANALYSIS OF SURVIVAL DATA UNDER PROPORTIONAL HAZARDS MODEL [J].
BRESLOW, NE .
INTERNATIONAL STATISTICAL REVIEW, 1975, 43 (01) :45-58
[3]   LIFE TESTING [J].
EPSTEIN, B ;
SOBEL, M .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1953, 48 (263) :486-502
[4]   Comparing survival of a sample to that of a standard population [J].
Finkelstein, DM ;
Muzikansky, A ;
Schoenfeld, DA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (19) :1434-1439
[5]  
Jung S.-H., 2013, Randomized phase II cancer clinical trials
[6]   Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test [J].
Kwak, Minjung ;
Jung, Sin-Ho .
STATISTICS IN MEDICINE, 2014, 33 (12) :2004-2016
[7]  
Lawless J.F, 2003, STAT MODELS METHODS, Vsecond, DOI DOI 10.1002/9781118033005
[8]   SAMPLE SIZE CALCULATIONS IN EXPONENTIAL LIFE TESTING [J].
NARULA, SC ;
LI, FS .
TECHNOMETRICS, 1975, 17 (02) :229-231
[9]   Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion [J].
Sun, Xiaoqun ;
Peng, Paul ;
Tu, Dongsheng .
CONTEMPORARY CLINICAL TRIALS, 2011, 32 (01) :108-113
[10]  
SWOG, CANC RES NETW CANC R